smallpox
Information
- Disease name
- smallpox
- Disease ID
- DOID:8736
- Description
- "A viral infectious disease that results in infection located in skin, has_material_basis_in Variola virus, which is transmitted by droplets from oral, nasal or pharyngeal mucosa, transmitted by contact with the body fluids, or transmitted by fomites. The infection results in formation of lesions, first on the face, hands and forearms and later on the trunk." [url:http\://www.who.int/csr/disease/smallpox/en/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05995275 | Active, not recruiting | Phase 1/Phase 2 | A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age | August 15, 2023 | June 13, 2025 |
| NCT02080767 | Available | Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure | |||
| NCT00038987 | Completed | Phase 1/Phase 2 | Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT | May 2002 | August 2002 |
| NCT00042094 | Completed | Phase 1 | Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax® | March 2002 | March 2003 |
| NCT00050505 | Completed | Phase 2 | Expanded Dryvax Dilution Study in Previously Vaccinated Adults | October 2002 | December 2003 |
| NCT00050518 | Completed | Phase 2 | APSV in Vaccinia Naive Adults | February 2003 | |
| NCT00053482 | Completed | Phase 2 | Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults | January 2003 | October 2003 |
| NCT00053495 | Completed | Phase 2 | Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination | January 2003 | November 2003 |
| NCT00063856 | Completed | Phase 1/Phase 2 | Dressing Preparations for Smallpox | July 2003 | June 2004 |
| NCT00068198 | Completed | Phase 1 | Human Immune Responses Smallpox | November 2004 | |
| NCT00079820 | Completed | Phase 1 | Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults | April 2004 | October 2006 |
| NCT00082446 | Completed | Phase 1 | Combination Study With MVA BN and Dryvax | May 2004 | August 2007 |
| NCT00123396 | Completed | N/A | VHA Clinicians and Bioterror Events: Interactive Web-based Learning | August 2004 | September 2007 |
| NCT00133575 | Completed | Phase 1/Phase 2 | ACAM 3000 MVA at Harvard Medical School | October 2005 | April 2008 |
| NCT00189943 | Completed | Phase 1 | Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects | April 2001 | July 2003 |
| NCT00189956 | Completed | Phase 2 | Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine. | April 2003 | December 2005 |
| NCT00189969 | Completed | Phase 1 | Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects | September 2003 | February 2006 |
| NCT00258947 | Completed | Phase 2 | Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults | September 2005 | January 2007 |
| NCT00928577 | Completed | Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®) | December 2008 | December 2015 | |
| NCT00032708 | Completed | Phase 2 | Dryvax Dilution-Prev Vacc Adults | April 2004 | November 2004 |
| NCT04971109 | Completed | Phase 3 | Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day | March 29, 2022 | May 12, 2023 |
| NCT05762523 | Completed | Phase 1 | Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years | May 18, 2019 | January 27, 2020 |
| NCT05846243 | Completed | Phase 2/Phase 3 | Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years | October 1, 2021 | April 1, 2022 |
| NCT05935917 | Completed | Phase 1 | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults | May 30, 2023 | September 27, 2023 |
| NCT05976100 | Completed | Phase 1 | Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years | September 4, 2020 | March 9, 2022 |
| NCT00316524 | Completed | Phase 2 | A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects | April 2006 | August 2007 |
| NCT00336635 | Completed | Phase 1 | Safety and Immunogenicity of CJ-50300 | June 2006 | February 2007 |
| NCT00437021 | Completed | Phase 1/Phase 2 | MVA Post-Event: Administration Timing and Boost Study | April 2007 | April 2009 |
| NCT00466245 | Completed | Phase 2 | Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine | July 2005 | June 2006 |
| NCT00607243 | Completed | Phase 2/Phase 3 | Safety and Efficacy of CJ-50300 in Healthy Volunteers | January 2008 | December 2008 |
| NCT00646152 | Completed | Phase 1 | Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study | March 24, 2008 | December 16, 2009 |
| NCT00686582 | Completed | Phase 2 | An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees | August 2008 | June 2009 |
| NCT00728689 | Completed | Phase 1 | Phase I Trial of an Investigational Small Pox Medication | August 2008 | October 2008 |
| NCT00857493 | Completed | Phase 2 | A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects | June 2009 | August 2010 |
| NCT00914732 | Completed | Phase 2 | Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally | February 2010 | April 2011 |
| NCT00927719 | Completed | Safety Surveillance Study of ACAM2000® Vaccinia Vaccine | December 2008 | December 31, 2017 | |
| NCT00026611 | Completed | Phase 2 | A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults | December 2001 | |
| NCT00998543 | Completed | A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain) | October 2006 | March 2012 | |
| NCT01056770 | Completed | Phase 3 | Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers | October 2009 | January 2011 |
| NCT01144637 | Completed | Phase 3 | A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects | February 2013 | June 2014 |
| NCT01317238 | Completed | Phase 3 | Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers | October 2010 | December 2011 |
| NCT01540929 | Completed | Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel | September 2009 | September 2012 | |
| NCT01668537 | Completed | Phase 2 | A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects | March 2013 | June 2014 |
| NCT01827371 | Completed | Phase 2 | Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE® | June 2013 | April 2015 |
| NCT02038881 | Completed | Phase 2 | Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection | April 28, 2014 | May 10, 2017 |
| NCT02474589 | Completed | Phase 3 | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat | June 19, 2015 | August 24, 2016 |
| NCT03699124 | Completed | Phase 3 | Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial | June 19, 2019 | June 22, 2020 |
| NCT04392739 | Completed | Phase 4 | Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG | July 19, 2019 | December 5, 2019 |
| NCT04485039 | Completed | Phase 4 | Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders | June 8, 2022 | April 23, 2023 |
| NCT04957485 | Completed | Phase 2 | Study to Assess the Safety and Pharmacokinetics of TPOXX® When Administered Orally for 28 Days | January 5, 2022 | May 5, 2023 |
| NCT00282581 | Terminated | Phase 1 | Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive | October 2006 | July 2007 |
| NCT00053508 | Terminated | Phase 2 | Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination | September 2002 | September 2003 |
| NCT00103584 | Unknown status | Phase 1/Phase 2 | Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers | October 2004 | July 2006 |
| NCT03972111 | Withdrawn | A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox | January 1, 2020 | September 30, 2024 | |
| NCT00389103 | Withdrawn | Phase 1 | Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD) | October 2006 | January 2007 |
- Disase is a (Disease Ontology)
- DOID:934
- Cross Reference ID (Disease Ontology)
- GARD:7444
- Cross Reference ID (Disease Ontology)
- ICD10CM:B03
- Cross Reference ID (Disease Ontology)
- ICD9CM:050
- Cross Reference ID (Disease Ontology)
- MESH:D012899
- Cross Reference ID (Disease Ontology)
- NCI:C35027
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:266193008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0037354
- Exact Synonym (Disease Ontology)
- Ordinary smallpox
- ICD10 preferred id (Insert disease from ICD10)
- D0000496
- ICD10 class code (Insert disease from ICD10)
- B03
- MeSH unique ID (MeSH (Medical Subject Headings))
- D012899